Latest current cash for CLVS: $58M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Clovis Oncology posts a current cash of $58M as of September 2022. That compares with $170M in the prior-year period — down 66.1% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
In the prior comparable period, Clovis Oncology's current cash was $170M. The latest reading is $58M — a 66.1% year-over-year decrease (period ending September 2022). Use the history and growth charts on this page for a longer lookback.
Current Cash is one piece of Clovis Oncology's financial statement story. At $58M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.
Context for CLVS's current cash usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Clovis Oncology's other metric pages and overview cover the third.
Judging Clovis Oncology against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in current cash easier to interpret. Start with $58M here, then scan peer and history charts to see if the gap is persistent.